Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Change in Acquisitions & Divestments (2016 - 2017)

Historic Change in Acquisitions & Divestments for Ocular Therapeutix (OCUL) over the last 3 years, with Q3 2017 value amounting to $3.0 million.

  • Ocular Therapeutix's Change in Acquisitions & Divestments fell 7956.96% to $3.0 million in Q3 2017 from the same period last year, while for Dec 2017 it was $38.2 million, marking a year-over-year decrease of 5265.48%. This contributed to the annual value of $38.2 million for FY2017, which is 5265.48% down from last year.
  • Ocular Therapeutix's Change in Acquisitions & Divestments amounted to $3.0 million in Q3 2017, which was down 7956.96% from $22.7 million recorded in Q2 2017.
  • Over the past 5 years, Ocular Therapeutix's Change in Acquisitions & Divestments peaked at $30.0 million during Q3 2015, and registered a low of $3.0 million during Q3 2017.
  • Its 3-year average for Change in Acquisitions & Divestments is $18.2 million, with a median of $16.0 million in 2016.
  • As far as peak fluctuations go, Ocular Therapeutix's Change in Acquisitions & Divestments soared by 666.67% in 2016, and later plummeted by 7956.96% in 2017.
  • Over the past 3 years, Ocular Therapeutix's Change in Acquisitions & Divestments (Quarter) stood at $15.0 million in 2015, then increased by 6.67% to $16.0 million in 2016, then tumbled by 81.25% to $3.0 million in 2017.
  • Its Change in Acquisitions & Divestments was $3.0 million in Q3 2017, compared to $22.7 million in Q2 2017 and $12.5 million in Q1 2017.